Mr. Moch brings more than 25 years of experience in managing and financing biomedical technologies, and has played a key role in building several life science companies. In this newly-created position, Mr. Moch will be responsible for overseeing corporate and financial strategy, business development and operations, reporting to George Painter, Ph.D., Chimerix’s President and Chief Executive Officer.
“With a rich pipeline of next-generation antiviral drug candidates, productive platform technology, an extraordinary library of new leads and supportive top-tier investors, Chimerix combines deep assets with the scientific heritage necessary to emerge at the forefront of antiviral drug development,” said Mr. Moch. “I am excited to join this veteran team. We have the opportunity to create much-needed new pharmaceutical products with promise in a broad range of challenging viral diseases.”
About Chimerix
Chimerix, Inc. discovers, develops and commercializes antiviral therapeutics with enhanced pharmaceutical properties for the treatment of a range of life-threatening diseases. Leveraging a powerful lipid technology, Chimerix is able to develop drug candidates with oral availability or topical applications with increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events. The company’s lead compound, CMX001, has shown promise as a broad-spectrum antiviral drug and is currently being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination, as well as for the treatment of infections that cause morbidity and mortality in immunocompromised patients such as cytomegalovirus (CMV) and BK virus. Chimerix’s pipeline includes an anti-HIV drug, CMX157, in late-stage preclinical studies. Chimerix is also advancing programs in hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.
SOURCE Chimerix, Inc.
CONTACT: Karen L. Bergman, or Susan M. Pietropaolo, both of BCC Partners,
for Chimerix, Inc., +1-650-575-1509, or +1-201-923-2049
